{"id":"W3092280067","doi":"10.1016/j.clbc.2020.09.014","title":"Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial","year":2020,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Eli Lilly Japan; Chugai Pharmaceutical; PharmaMar; AstraZeneca Australia; Kyowa Hakko Kirin; Astellas Pharma; Eisai; GlaxoSmithKline Australia; Puma Biotechnology; Genentech; Seattle Genetics; Genomic Health; AbbVie; Mount Sylvia Diatomite; Roche; Daiichi-Sankyo; Teva Pharmaceutical Industries; Pfizer Australia; Celgene; Novartis; Merck; GlaxoSmithKline; British Microcirculation Society; Amgen; Ontario Brain Institute; Pfizer; Bayer; AstraZeneca; Eli Lilly and Company","keywords":"Neratinib; Medicine; Breast cancer; Oncology; Hormone receptor; Internal medicine; Stage (stratigraphy); Gynecology; Cancer; Trastuzumab","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003401747,0.001338584,0.002601004,0.000234542,0.0002965805,0.001447365,0.0006093921,0.0007644151,0.003748509],"category_scores_gemma":[0.002213112,0.0002285987,0.002436073,0.0003016479,0.000519104,0.001290692,0.0004748111,0.002900769,0.0009488712],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008249446,"about_ca_system_score_gemma":0.0007184367,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003938419,"about_ca_topic_score_gemma":0.001614336,"domain_scores_codex":[0.9993179,0.0003095994,0.00004464318,0.00008942633,0.00008325598,0.0001551307],"domain_scores_gemma":[0.9991971,0.0002482556,0.0001156106,0.00009314445,0.00008594398,0.0002599432],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6076659,0.006986404,0.009828628,0.003336925,0.008060589,0.0006703092,0.000360381,0.0149218,0.02341738,0.001957823,0.03795912,0.2848347],"study_design_scores_gemma":[0.7289104,0.1355949,0.05477099,0.0005351469,0.008507668,0.002195588,0.0003085999,0.006823496,0.01121615,0.00632052,0.04458794,0.0002285843],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9488164,0.02060492,0.002233394,0.003427825,0.0007281826,0.00111672,0.01014204,0.0003008179,0.01262974],"genre_scores_gemma":[0.9643527,0.006381806,0.001844665,0.002844501,0.000250645,0.000707819,0.01616977,0.0001320296,0.007316187],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003748509,"threshold_uncertainty_score":0.01799035,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1250320236614364,"score_gpt":0.4544052343978909,"score_spread":0.3293732107364545,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}